| 产品描述: | RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity |
| 靶点: |
Antibiotic;Bacterial |
| 体外研究: |
RNPA1000 displays antimicrobial activity toward Gram-positive bacteria and little or no toxicity toward human cells. RNPA1000 limits S. aureus mRNA turnover and growth. RNPA1000 also limits growth of other important Gram-positive bacterial pathogens, exhibits antimicrobial efficacy against biofilm associated S. aureus and protects against the S. aureus pathogenesis in an animal model of infection. RNPA1000 (IC50= 100-125 µM), does not affect the activity of the commercially available E. coli RNase HI, RNase A, RNase I or in-house purified S. aureus RNase J1 at any concentration tested (0-750 µM), but does mildly inhibit E. coli RNase III activity (IC50= 500-750 µM) |
| 参考文献: |
1. Eidem TM, et al. Drug-eluting cements for hard tissue repair: a comparative study using vancomycin and RNPA1000 to inhibit growth of Staphylococcus aureus. J Biomater Appl. 2014 Apr;28(8):1235-46. 2. Eidem TM, et al. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28. 3. Patrick D Olson, et al. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis. PLoS Pathog. 2011 Feb 10;7(2):e1001287. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.154 ml |
10.769 ml |
21.537 ml |
| 5 mM |
0.431 ml |
2.154 ml |
4.307 ml |
| 10 mM |
0.215 ml |
1.077 ml |
2.154 ml |
| 50 mM |
0.043 ml |
0.215 ml |
0.431 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |